GlassScriptPhysician profile
Claudia Molles
NPI 1932557675
$1,965.25
in general payments reported to CMS, 2019-2025
18 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.00 · 2024: $563 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,941.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $434.82 | 2024-2025 | Repatha, Otezla, Otezla |
| Boston Scientific Corporation | $299.22 | 2024-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $254.87 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $158.15 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Optinose US, INC. | $149.96 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.81 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $93.88 | 2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $75.42 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $74.02 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.92 | 2024-2025 | |
| Astellas Pharma US INC | $57.89 | 2024-2025 | Veozah |
| Pfizer INC. | $36.40 | 2025 | |
| Hologic Sales and Service, LLC | $32.84 | 2024 | Aptima |
| Dexcom, INC. | $25.96 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $24.91 | 2025 | Elaprase |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $19.21 | 2024 | Zoryve |
| Glaxosmithkline, LLC. | $17.97 | 2024 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Molles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.